Search Result

Results for "

FLT3 kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FLT3 (117) AAK1 (2) Akt (8) AMPK (2) Antibiotic (1) Apoptosis (52) ATP Synthase (1) Aurora Kinase (12) Autophagy (9) Bacterial (1) Bcr-Abl (12) Btk (1) c-Fms (7) c-Kit (31) c-Met/HGFR (7) c-Myc (1) CaMK (1) Casein Kinase (1) Caspase (3) CDK (7) Checkpoint Kinase (Chk) (1) Creatine Kinase (1) Cyclin G-associated Kinase (GAK) (1) Discoidin Domain Receptor (2) Drug Metabolite (1) DYRK (2) EGFR (1) Enolase (1) Ephrin Receptor (2) Epigenetic Reader Domain (1) ERK (3) Eukaryotic Initiation Factor (eIF) (1) FAK (1) Ferroptosis (1) FGFR (15) Haspin Kinase (2) HDAC (1) HSP (1) Insulin Receptor (1) IRAK (3) Isotope-Labeled Compounds (6) JAK (8) Ligands for Target Protein for PROTAC (1) LIM Kinase (LIMK) (2) MAP3K (1) MAP4K (2) MDM-2/p53 (1) MELK (1) Mitochondrial Metabolism (1) Mitosis (1) MNK (3) NF-κB (1) NO Synthase (3) p38 MAPK (2) PAK (1) PARP (1) PDGFR (31) PI3K (1) Pim (1) PKA (1) PKC (4) PROTACs (8) RAD51 (3) Ras (1) Reactive Oxygen Species (ROS) (3) Reference Standards (14) RET (11) Ribosomal S6 Kinase (RSK) (1) ROS Kinase (1) Salt-inducible Kinase (SIK) (2) SnRK (1) Src (4) STAT (10) STK33 (1) Syk (8) TAM Receptor (4) Target Protein Ligand-Linker Conjugates (1) Tie (2) Trk Receptor (8) Tyrosinase (1) ULK (1) VEGFR (29) Wee1 (1)
By Research Areas:	Cancer (134) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (20) Metabolic Disease (2) Neurological Disease (4)

By Targets:

FLT3 (117)

AAK1 (2)

Akt (8)

AMPK (2)

Antibiotic (1)

Apoptosis (52)

ATP Synthase (1)

Aurora Kinase (12)

Autophagy (9)

Bacterial (1)

Bcr-Abl (12)

Btk (1)

c-Fms (7)

c-Kit (31)

c-Met/HGFR (7)

c-Myc (1)

CaMK (1)

Casein Kinase (1)

Caspase (3)

CDK (7)

Checkpoint Kinase (Chk) (1)

Creatine Kinase (1)

Cyclin G-associated Kinase (GAK) (1)

Discoidin Domain Receptor (2)

Drug Metabolite (1)

DYRK (2)

EGFR (1)

Enolase (1)

Ephrin Receptor (2)

Epigenetic Reader Domain (1)

ERK (3)

Eukaryotic Initiation Factor (eIF) (1)

FAK (1)

Ferroptosis (1)

FGFR (15)

Haspin Kinase (2)

HDAC (1)

HSP (1)

Insulin Receptor (1)

IRAK (3)

Isotope-Labeled Compounds (6)

JAK (8)

Ligands for Target Protein for PROTAC (1)

LIM Kinase (LIMK) (2)

MAP3K (1)

MAP4K (2)

MDM-2/p53 (1)

MELK (1)

Mitochondrial Metabolism (1)

Mitosis (1)

MNK (3)

NF-κB (1)

NO Synthase (3)

p38 MAPK (2)

PAK (1)

PARP (1)

PDGFR (31)

PI3K (1)

Pim (1)

PKA (1)

PKC (4)

PROTACs (8)

RAD51 (3)

Ras (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (14)

RET (11)

Ribosomal S6 Kinase (RSK) (1)

ROS Kinase (1)

Salt-inducible Kinase (SIK) (2)

SnRK (1)

Src (4)

STAT (10)

STK33 (1)

Syk (8)

TAM Receptor (4)

Target Protein Ligand-Linker Conjugates (1)

Tie (2)

Trk Receptor (8)

Tyrosinase (1)

ULK (1)

VEGFR (29)

Wee1 (1)

By Research Areas:

Cancer (134)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (20)

Metabolic Disease (2)

Neurological Disease (4)

144

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: FLT3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13001

Quizartinib 40+ Cited Publications AC220	FLT3 Apoptosis PDGFR c-Kit	Cancer
Quizartinib (AC220) is an orally active, potent and selective *FLT3* inhibitor. Quizartinib inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib can be used for the research of cancer .

HY-13223

Crenolanib 15+ Cited Publications CP-868596	FLT3 PDGFR Autophagy	Cancer
Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases *FLT3* and PDGFRα/β with K_ds of 0.74 nM and 2.1 nM/3.2 nM, respectively.

HY-12044

Cabozantinib S-malate Maximum Cited Publications 56 Publications Verification XL184 S-malate; BMS-907351 S-malate	VEGFR Apoptosis	Cancer
Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and *Flt3* with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-10339

KW-2449 5+ Cited Publications	FLT3 FGFR Bcr-Abl Aurora Kinase Apoptosis	Cancer
KW-2449 is a multi-targeted kinase inhibitor of *FLT3, ABL, ABL ^T315I* and Aurora kinase with IC₅₀s of 6.6, 14, 4 and 48 nM, respectively.

HY-50514

AT9283 5+ Cited Publications	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and *Flt3* (IC₅₀s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-10987A

ENMD-2076 4 Publications Verification	Aurora Kinase FLT3 VEGFR FGFR PDGFR Src Apoptosis	Cancer
ENMD-2076 is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, *Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα*, respectively.

HY-145015

Tuspetinib HM43239	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) is an orally active and selective *FLT3* inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells .

HY-130665

TL12-186 1 Publications Verification	PROTACs CDK	Cancer
TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include CDK, BTK, *FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A* (IC₅₀=73 nM) and CDK9/cyclin T1 (IC₅₀=55 nM) .

HY-101549

MRX-2843 5+ Cited Publications UNC2371	FLT3	Cancer
MRX-2843 (UNC2371) is an orally active, ATP-competitive dual MERTK and *FLT3* tyrosine kinases inhibitor (TKI) with enzymatic IC₅₀s of 1.3 nM for MERTK and 0.64 nM for FLT3, respectively .

HY-15002

AST 487 5 Publications Verification NVP-AST 487	RET FLT3 VEGFR c-Kit Bcr-Abl	Cancer
AST 487 is a RET kinase inhibitor with IC₅₀ of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits *Flt-3* with IC₅₀ of 520 nM.

HY-100867A

Mivavotinib monohydrochloride TAK-659 monohydrochloride; CB-659 monohydrochloride	Syk FLT3	Cancer
TAK-659 hydrochloride is a highly potent, selective, reversible and orally available dual inhibitor of *spleen tyrosine kinase* (SYK)** and fms related tyrosine kinase 3 (FLT3), with an IC₅₀ of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 hydrochloride induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL) .

HY-172581

Clifutinib	FLT3 Apoptosis Ras p38 MAPK PI3K Akt JAK STAT	Cancer
Clifutinib is an orally active and selective internal tandem duplication mutation of FMS-like tyrosine kinase 3 (FLT3-ITD) inhibitor with an IC₅₀ value of 15.1 nM. Clifutinib exerts strong antiproliferative effects on FLT3-ITD acute myeloid leukemia (AML) cell lines (MV-4-11: IC₅₀ = 1.5 nM; MOLM-13: IC₅₀ = 1.4 nM). Clifutinib inhibits the activity of FLT3-ITD kinase and blocks the downstream RAS/MAPK, PI3K/AKT, and JAK/STAT5 signaling pathways of FLT3. Clifutinib induces apoptosis of acute myeloid leukemia (AML) cells with FLT3-ITD mutations. Clifutinib demonstrates significant antitumor efficacy in mice bearing MV-4-11 or MOLM-13 xenografts. Clifutinib is promising for research of relapsed/refractory FLT3-ITD-positive acute myeloid leukemia .

HY-15590

AZ-23 3 Publications Verification AZD1332	Trk Receptor	Cancer
AZ-23 is an ATP-competitive and orally bioavailable *Trk kinase* A/B/C inhibitor with IC₅₀*s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3*), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.

HY-B0791

Altiratinib 1 Publications Verification DCC-2701	VEGFR c-Met/HGFR FLT3 Trk Receptor	Cancer
Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC₅₀s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, *FLT3, Trk1, Trk2, and Trk3* respectively.

HY-10207

Dovitinib lactate 10+ Cited Publications CHIR-258 lactate; TKI-258 lactate	FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for *FLT3, c-Kit, FGFR1/3, VEGFR1/2/3* and PDGFRα/β, respectively .

HY-13016S

Cabozantinib-d6 XL184-d₆; BMS-907351-d₆	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-125510

UNC2541 1 Publications Verification	TAM Receptor	Neurological Disease Inflammation/Immunology
UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor, binds in the MerTK ATP pocket, with an IC₅₀ of 4.4 nM, more selective over Axl, Tyro3 and Flt3. UNC2541 inhibits phosphorylated MerTK (pMerTK; EC₅₀, 510 nM). UNC2541 abolishes the analgesic and anti-inflammatory effects of ozone in vivo and in vitro .

HY-10206

Amuvatinib 5+ Cited Publications MP470; HPK 56	c-Kit PDGFR RAD51 FLT3 c-Met/HGFR RET Apoptosis	Cancer
Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, *Flt3, c-Met* and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .

HY-14217

Quizartinib dihydrochloride 40+ Cited Publications AC220 dihydrochloride	FLT3 Apoptosis PDGFR c-Kit	Cancer
Quizartinib (AC220) dihydrochloride is an orally active, potent and selective *FLT3* inhibitor. Quizartinib dihydrochloride inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib dihydrochloride inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib dihydrochloride can be used for the research of cancer .

HY-13838

PLX647	c-Fms c-Kit	Cancer
PLX647 is an orally active, highly specific dual FMS and KIT kinase inhibitor, with IC₅₀s of 28 and 16 nM, respectively. PLX647 shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC₅₀s=91 and 130 nM, respectively) .

HY-18161

CCT241736	FLT3 Aurora Kinase	Cancer
CCT241736 is a potent and orally bioavailable dual *FLT3* and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC₅₀, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).

HY-145723

MAX-40279 1 Publications Verification	FLT3 FGFR	Inflammation/Immunology Cancer
MAX-40279 is a dual and orally active inhibitor of *FLT3* kinase and FGFR kinase. MAX-40279 is also effective against the FLT3 mutants such as FLT3 ^D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201). MAX-40279 inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 can be used for the research of acute myelogenous leukemia (AML) .

HY-13072

Cenisertib 1 Publications Verification AS-703569; R-763	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-159953

*IRAK1/4/pan-FLT3* Kinase-IN-1**	IRAK FLT3	Inflammation/Immunology Cancer
IRAK1/4/pan-FLT3 Kinase-IN-1 is an orally active, potent and selective *IRAK/pan-FLT3* *kinase* inhibitor with IC₅₀s of 5 nM, 0.6 nM and <0.5 nM against IRAK1, IRAK4 and FLT3, respectively. IRAK1/4/pan-FLT3 Kinase-IN-1 can be used for research on AML .

HY-15003

ATH686	FLT3 Apoptosis	Cancer
ATH686 is a potent, selective and ATP-competitive *FLT3* inhibitor. ATH686 target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition. ATH686 has antileukemic effects .

HY-108263

3-Hydroxy Midostaurin CGP52421	FLT3	Cancer
3-Hydroxy Midostaurin (CGP 52421), a metabolite of PKC412, effectively inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC₅₀s of approximately 132 nM and 9.8 μM in culture medium and plasma, respectively. 3-Hydroxy Midostaurin is less selective but more cytotoxic than PKC412 .

HY-P5438

Srctide	Btk c-Kit FAK FLT3 Insulin Receptor	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-115778

UNC3133	TAM Receptor FLT3	Inflammation/Immunology Cancer
UNC3133 is an orally active, limitedly selective MerTK inhibitor with an IC₅₀ of 3.0 nM. UNC3133 inhibits Axl, Tyro3 and *Flt3* kinases, with IC₅₀ values of 17 nM, 31 nM and 6.8 nM, respectively. UNC3133 is applicable to the research of inflammatory diseases and cancers .

HY-18179

AZD2932	PDGFR VEGFR FLT3 c-Kit	Cancer
AZD2932 is a potent and multi-targeted kinase inhibitor VEGFR2, PDGFβ, *Flt-3* and c-Kit with IC₅₀s of 8, 4, 7 and 9 nM in cell assay, respectively.

HY-179094

PSP-0119	PROTACs IRAK NF-κB Enolase	Inflammation/Immunology Cancer
PSP-0119 is a highly efficient and effective PROTAC degrader targeting IRAK4 (IC₅₀ = 2.83 nM). PSP-0119 can inhibit IRAK4 kinase activity, NF-κβ activity, and IL-1β-induced IRAK4 phosphorylation. PSP-0119 degrades IRAK4 in FLT3-mutant AML cell lines, sparing FLT3-wild-type AML cells, FLT3-wild-type samples, and normal bone marrow. PSP-0119 downregulates alpha-enolase (eNOS) of MOLM-13 cells. PSP-0119 can be used for the study of Acute Myeloid Leukemia (AML) .

HY-118304B

AKN-028 acetate	FLT3 Apoptosis Caspase	Cancer
AKN-028 acetate, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6 nM. AKN-028 acetate inhibits FLT3 autophosphorylation. AKN-028 acetate induces dose-dependent cytotoxic response (mean IC50=1 μM). AKN-028 acetate induces apoptosisby activation of caspase 3. AKN-028 acetate can be used in research of acute myeloid leukemia (AML).

HY-13223A

Crenolanib benzenesulfonate 15+ Cited Publications CP 868596-26	Autophagy PDGFR FLT3	Cancer
Crenolanib benzenesulfonate is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases *FLT3* and PDGFRα/β with K_ds of 0.74 nM and 2.1 nM/3.2 nM, respectively.

HY-13016S1

Cabozantinib-d4 XL184-d₄; BMS-907351-d₄	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-10987

ENMD-2076 Tartrate 4 Publications Verification	Aurora Kinase FLT3 VEGFR FGFR Src PDGFR Apoptosis	Cancer
ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, *Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα*, respectively.

HY-100867

Mivavotinib TAK-659; CB-659	Syk FLT3	Cancer
TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of *spleen tyrosine kinase* (SYK)** and fms related tyrosine kinase 3 (FLT3), with an IC₅₀ of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL) .

HY-112475

Flt-3 Inhibitor III	Tie FLT3	Cancer
Flt-3 Inhibitor III is a potent and selective **FLT3 kinase** inhibitor with an ₅₀ of 50 nM. Flt-3 Inhibitor III shows less active against other kinases. Flt-3 Inhibitor III has anticancer effects .

HY-13223R

Crenolanib (Standard) CP-868596 (Standard)	FLT3 PDGFR Autophagy Reference Standards	Cancer
Crenolanib (Standard) is the analytical standard of Crenolanib. This product is intended for research and analytical applications. Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively.

HY-E70724

**FLT3 ITD Recombinant Human Active Protein Kinase**	FLT3	Cancer
FLT3 (FMS-like tyrosine kinase 3, CD135) is a type 3 receptor tyrosine kinase that plays important roles in cell survival, proliferation, and differentiation during normal hematopoiesis. FLT3 is one of the most frequently mutated genes in acute myeloid leukemia (AML). FLT3 ITD is a internal tandem duplication (ITD) mutation of FLT3 that may be present in AML cells. FLT3 ITD Recombinant Human Active Protein Kinase is a recombinant FLT3 ITD protein that can be used to study FLT3 ITD-related functions .

HY-128571

FLT3-IN-4	FLT3	Cancer
FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC₅₀=7 nM) inhibitor for treating acute myelogenous leukemia .

HY-143286A

PF15 TFA	PROTACs FLT3	Cancer
PF15 TFA is a PROTAC connected by ligands for *FLT3* kinase and CRBN. PF15 TFA is a high selective FLT3-ITD degrader，with a DC50 of 76.7 nM. PF15 TFA significantly inhibits the proliferation of FLT3-ITD-positive cells，can down-regulate the phosphorylation of FLT3 and STAT5. PF15 TFA also inhibits tumor growth in mouse models and can be used in study of leukemia .

HY-E70723

**FLT3 D835Y Recombinant Human Active Protein Kinase**	FLT3	Cancer
FLT3 (FMS-like tyrosine kinase 3, CD135) is a type 3 receptor tyrosine kinase that plays important roles in cell survival, proliferation, and differentiation during normal hematopoiesis. FLT3 is one of the most frequently mutated genes in acute myeloid leukemia (AML). FLT3 D835Y is the most frequent kinase domain mutation, converting aspartic acid to tyrosine. FLT3 D835Y Recombinant Human Active Protein Kinase is a recombinant FLT3 D835Y protein that can be used to study FLT3 D835Y-related functions .

HY-134481

FLT3-IN-10	FLT3	Cancer
FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 has the potential for the research of FLT3-mutated acute myeloid leukemia (AML) .

HY-16449

SB1578 CT-1578	JAK FLT3	Inflammation/Immunology
SB1578 (CT-1578) is a selective JAK2 and *FLT3* inhibitor with an IC₅₀ of 46 nM and 60 nM, respectively. SB1578 exhibits high selectivity for other kinase targets. SB1578 can be used for the study of non-oncology indication rheumatoid arthritis .

HY-B0062

Dovitinib lactate hydrate TKI258 lactate hydrate; CHIR-258 lactate hydrate	FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for *FLT3, c-Kit, FGFR1/3, VEGFR1/2/3* and PDGFRα/β, respectively .

HY-10206A

Amuvatinib hydrochloride MP470 hydrochloride; HPK 56 hydrochloride	c-Kit PDGFR RAD51 FLT3 c-Met/HGFR RET	Cancer
Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, *Flt3, c-Met* and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .

HY-145015A

Tuspetinib hydrate HM43239 hydrate	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) hydrate is an orally active and selective *FLT3* inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib hydrate inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib hydrate inhibits the proliferation and induces the apoptosis of leukemic cells .

HY-145015B

Tuspetinib dihydrochloride HM43239 dihydrochloride	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) dihydrochloride is an orally active and selective *FLT3* inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib dihydrochloride inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib dihydrochloride inhibits the proliferation and induces the apoptosis of leukemic cells .

HY-143286

PF15	PROTACs FLT3	Cancer
PF15 is a PROTAC connected by ligands for **FLT3 kinase and CRBN. PF15 is a high selective FLT3-ITD degrader, with a DC₅₀ of 76.7 nM. PF15 significantly inhibits the proliferation of FLT3-ITD**-positive cells, can down-regulate the phosphorylation of *FLT3* and STAT5. PF15 also inhibits tumor growth in mouse models and can be used in study of leukemia .

HY-175274

MolPort-002-705-878	FLT3	Cancer
MolPort-002-705-878 is a highly selective FMS-like tyrosine kinase 3 (FLT3) inhibitor with a binding affinity of −11.33 kcal/mol. MolPort-002-705-878 inhibits the proliferation of FLT3-mutated acute myeloid leukemia (AML) cells. MolPort-002-705-878 is promising for research of FLT3-mutated AML .

HY-161708

PROTAC FLT3/CDKs degrader-1	PROTACs CDK FLT3	Cancer
PROTAC FLT3/CDKs degrader-1 (Compound C3) is a degrader for cyclin-dependent kinases (DC₅₀ is 18.73 nM for CDK2) and the FMS-like tyrosine kinase 3 (FLT3). PROTAC FLT3/CDKs degrader-1 induces differentation of HL-60 (72.77% differentation at 6.25 nM), inhibits proliferation of AML cells, with IC₅₀s of 2.9-37 nM. PROTAC FLT3/CDKs degrader-1 is potential for ameliorating acute myeloid leukemia. (Pink: ligand for target protein FLT3/CDKs ligand-1 (HY-161709); Black: linker (HY-W012935); Black: ligand for E3 ligase Thalidomide 5-fluoride (HY-W087383))

Cat. No.	Product Name	Target	Research Area

HY-P5438

Srctide	Btk c-Kit FAK FLT3 Insulin Receptor	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P5527F

FAM-CSKtide	Peptides	Others
FAM-CSKtide is a biological active peptide. (This is a FAM labeled peptide substrate (Abs/Em = 494/521 nm) for C-terminal Src kinase (Csk) and many other kinases such as Axl, cKit, ERBB4, Fes, Flt3, IGF-1 R, MET, MUSK, PYK2, Ret, TIE2, TrkA, VEGF-R1 and VEGF-R2.)

Cat. No.	Product Name	Target	Research Area	Image

HY-P991114

Adezkibart	FLT3	Inflammation/Immunology
Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to *FLT3LG* to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases .

Species:	Human (7) Rhesus Macaque (1) Rat (1) Mouse (4) Cynomolgus (1) Pig (1)
Tag:	His (10) Tag Free (1) Avi (2) Fc (3)
Source:	HEK293 (7) CHO (1) Sf9 insect cells (3) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P70178

	FLT3 Protein, Human (HEK293, hFc, solution) 2 Publications Verification rHuReceptor-Type Tyrosine-Protein kinase FLT3/FLT3, Fc; Receptor-Type Tyrosine-Protein kinase FLT3; FL Cytokine Receptor; Fetal Liver kinase-2; FLK-2; Fms-Like Tyrosine kinase 3; FLT-3; Stem Cell Tyrosine kinase 1; STK-1; CD135; FLT3; FLK2; STK1	Human	HEK293
	FLT3 is a tyrosine-protein kinase receptor that regulates differentiation, proliferation, and survival of hematopoietic progenitor cells and dendritic cells. It phosphorylates downstream effectors such as SHC1 and AKT1, activating signaling cascades involving MTOR, RAS, and MAP kinases. FLT3 Protein, Human (HEK293, Fc, solution) is the recombinant human-derived FLT3 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P70563

	FLT3LG Protein, Mouse (HEK293, His) 1 Publications Verification Fms-related tyrosine kinase 3 ligand (FLT3L); SL cytokine; FLT3 ligand	Mouse	HEK293
	FLT3LG protein, a potent stimulator, activates FLT3, synergizing with colony-stimulating factors and interleukins. Its homodimeric form, especially in the soluble isoform, effectively promotes the expansion and differentiation of hematopoietic progenitor cells. The protein's significance lies in orchestrating key processes within the hematopoietic system. FLT3LG Protein, Mouse (HEK293, His) is the recombinant mouse-derived FLT3LG protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P70544

	FLT3LG Protein, Human (HEK293, His) Fms-Felated Tyrosine kinase 3 Ligand; FLT3 Ligand; FLT3L; SL Cytokine; FLT3LG	Human	HEK293
	FLT3LG protein, a potent stimulator of early hematopoietic cell proliferation, activates FLT3 and synergizes with colony-stimulating factors and interleukins. As a homodimer, especially in isoform 2, it crucially promotes expansion and differentiation of hematopoietic progenitor cells. FLT3LG's collaborative signaling with other molecules underscores its significance in regulating hematopoiesis and maintaining hematopoietic system balance. FLT3LG Protein, Human (HEK293, His) is the recombinant human-derived FLT3LG protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P73066

	FLT3LG Protein, Human (sf9, His) Fms-related tyrosine kinase 3 ligand; FLT3 Ligand; FLT3L; SL Cytokine; FLT3LG	Human	Sf9 insect cells
	FLT3LG protein, a potent stimulator of early hematopoietic cell proliferation, activates FLT3 and synergizes with colony-stimulating factors and interleukins. As a homodimer, especially in isoform 2, it crucially promotes expansion and differentiation of hematopoietic progenitor cells. FLT3LG's collaborative signaling with other molecules underscores its significance in regulating hematopoiesis and maintaining hematopoietic system balance. FLT3LG Protein, Human (sf9, His) is the recombinant human-derived FLT3LG protein, expressed by Sf9 insect cells , with N-His labeled tag.

HY-P73067

	FLT3LG Protein, Mouse (HEK293, Fc) Fms-related tyrosine kinase 3 ligand; FLT3 Ligand; FLT3L; SL Cytokine; FLT3LG	Mouse	HEK293
	FLT3LG protein, a potent stimulator, activates FLT3, synergizing with colony-stimulating factors and interleukins. Its homodimeric form, especially in the soluble isoform, effectively promotes the expansion and differentiation of hematopoietic progenitor cells. The protein's significance lies in orchestrating key processes within the hematopoietic system. FLT3LG Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived FLT3LG protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P74150

	FLT3LG Protein, Rat (sf9, His) Fms-related tyrosine kinase 3 ligand; FLT3 Ligand; FLT3L; SL Cytokine; FLT3LG	Rat	Sf9 insect cells
	The FLT3LG protein has the same protein-binding and receptor tyrosine kinase-binding activities predicted to positively regulate natural killer cell proliferation. Intended to be located on the cell surface and extracellular space, it serves as an intrinsic component on the outside of the plasma membrane. FLT3LG Protein, Rat (sf9, His) is the recombinant rat-derived FLT3LG protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P700238AF

	Animal-Free FLT3LG Protein, Pig (His) Fms-Felated Tyrosine kinase 3 Ligand; FLT3 Ligand; FLT3L; SL Cytokine; FLT3LG	Pig	E. coli
	FLT3LG protein, a potent stimulator of early hematopoietic cell proliferation, activates FLT3 and synergizes with colony-stimulating factors and interleukins. As a homodimer, especially in isoform 2, it crucially promotes expansion and differentiation of hematopoietic progenitor cells. FLT3LG's collaborative signaling with other molecules underscores its significance in regulating hematopoiesis and maintaining hematopoietic system balance. Animal-Free FLT3LG Protein, Pig (His) is the recombinant pig-derived animal-FreeFlt-3 Ligand protein, expressed by E. coli, with C-His labeled tag. This product is for cell culture use only.

HY-P704173

	FLT3LG Protein, Human (HEK293, Fc) Fms-related tyrosine kinase 3 ligand; FLT3 ligand; FLT3L; SL cytokine; FLT3LG	Human	HEK293
	FLT3LG protein, a potent stimulator of early hematopoietic cell proliferation, activates FLT3 and synergizes with colony-stimulating factors and interleukins. As a homodimer, especially in isoform 2, it crucially promotes expansion and differentiation of hematopoietic progenitor cells. FLT3LG's collaborative signaling with other molecules underscores its significance in regulating hematopoiesis and maintaining hematopoietic system balance. FLT3LG Protein, Human (HEK293, Fc) is the recombinant human-derived FLT3 Ligand protein, expressed by HEK293, with C-hFc labeled tag.

HY-P702754

	FLT3 Protein, Human (Active, Biotinylated, sf9, His, Avi) FLT3; fms-related tyrosine kinase 3; receptor-type tyrosine-protein kinase FLT3; CD135; FLK2; STK1; STK-1; CD135 antigen; FL cytokine receptor; fetal liver kinase 2; fms-like tyrosine kinase 3; stem cell tyrosine kinase 1; growth factor receptor tyrosine kinase type III; FLK-2	Human	Sf9 insect cells
	FLT3 is a tyrosine-protein kinase receptor that regulates differentiation, proliferation, and survival of hematopoietic progenitor cells and dendritic cells. It phosphorylates downstream effectors such as SHC1 and AKT1, activating signaling cascades involving MTOR, RAS, and MAP kinases. FLT3 Protein, Human (Biotinylated, sf9, His, Avi) is the recombinant human-derived FLT3, expressed by Sf9 insect cells, with Avi, His labeled tag. The total length of FLT3 Protein, Human (Biotinylated, sf9, His, Avi) is 370 a.a..

HY-P705022

	FLT3 Protein, Human (Biotinylated, HEK293, His-Avi) FLT3; fms-related tyrosine kinase 3; receptor-type tyrosine-protein kinase FLT3; CD135; FLK2; STK1; STK-1; CD135 antigen; FL cytokine receptor; fetal liver kinase 2; fms-like tyrosine kinase 3; stem cell tyrosine kinase 1; growth factor receptor tyrosine kinase type III; FLK-2	Human	HEK293

HY-P72802

	FLT3LG Protein, Macaca nemestrina/Cynomolgus Fms related receptor tyrosine kinase 3 ligand; FLT3LG; FLT-3 Ligand	Rhesus Macaque;Cynomolgus	E. coli
	FLT3LG protein, a potent stimulator of early hematopoietic cell proliferation, activates FLT3 and synergizes with colony-stimulating factors and interleukins. As a homodimer, especially in isoform 2, it crucially promotes expansion and differentiation of hematopoietic progenitor cells. FLT3LG's collaborative signaling with other molecules underscores its significance in regulating hematopoiesis and maintaining hematopoietic system balance. FLT3LG Protein, Macaca nemestrina/Cynomolgus is the recombinant Rhesus Macaque-derived FLT3LG protein, expressed by E. coli , with tag free.

HY-P70544G

	GMP FLT3LG Protein, Human (HEK293, His) Fms-related tyrosine kinase 3 ligand; FLT3L; SL cytokine; FLT3LG	Human	HEK293
	FLT3LG protein, a potent stimulator of early hematopoietic cell proliferation, activates FLT3 and synergizes with colony-stimulating factors and interleukins. As a homodimer, especially in isoform 2, it crucially promotes expansion and differentiation of hematopoietic progenitor cells. FLT3LG's collaborative signaling with other molecules underscores its significance in regulating hematopoiesis and maintaining hematopoietic system balance. GMP FLT3LG Protein, Human (HEK293, His) is the recombinant human-derived FLT3LG protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P7354

	FLT3LG Protein, Mouse (CHO, His) rMuFLT-3 Ligand, His; Fms-related tyrosine kinase 3 ligand; SL cytokine; FLT3lg	Mouse	CHO
	FLT3LG protein, a potent stimulator of early hematopoietic cell proliferation, activates FLT3 and synergizes with colony-stimulating factors and interleukins. As a homodimer, especially in isoform 2, it crucially promotes expansion and differentiation of hematopoietic progenitor cells. FLT3LG's collaborative signaling with other molecules underscores its significance in regulating hematopoiesis and maintaining hematopoietic system balance. FLT3LG Protein, Mouse (CHO, His) is the recombinant mouse-derived FLT3LG protein, expressed by CHO cells, with C-His labeled tag.

HY-P700177AF

	Animal-Free FLT3LG Protein, Mouse (His) rMuFLT-3 Ligand, His; Fms-related tyrosine kinase 3 ligand; SL cytokine; FLT3lg	Mouse	E. coli
	FLT3LG protein, a potent stimulator, activates FLT3, synergizing with colony-stimulating factors and interleukins. Its homodimeric form, especially in the soluble isoform, effectively promotes the expansion and differentiation of hematopoietic progenitor cells. The protein's significance lies in orchestrating key processes within the hematopoietic system. Animal-Free FLT3LG Protein, Mouse (His) is the recombinant mouse-derived animal-FreeFLT3LG protein, expressed by E. coli , with C-His labeled tag. This product is for cell culture use only.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-10230S

Midostaurin-d5
Midostaurin-d₅ (PKC412-d₅) is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM .

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively .

HY-13001S

Quizartinib-d8

Quizartinib (AC220)-d₈ is deuterium labeled Quizartinib (HY-13001). Quizartinib is an orally active, potent and selective FLT3 inhibitor. Quizartinib inhibits kinase activity of mutant-FLT3, -PDGFRA and -KIT isoforms and inhibits autophosphorylation. Quizartinib inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib can be used for the research of cancer .

HY-108263S

3-Hydroxy Midostaurin-d5
3-Hydroxy Midostaurin-d₅ is a deuterium labeled 3-Hydroxy Midostaurin. 3-Hydroxy Midostaurin is a metabolite of PKC412, which effectively inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC₅₀s of approximately 132 nM and 9.8 μM in culture medium and plasma, respectively .

HY-W751180

3-Hydroxy Midostaurin-13C6

3-Hydroxy Midostaurin- ¹³C₆ (CGP52421- ¹³C₆) is the ¹³C-labeled 3-Hydroxy Midostaurin (HY-108263). 3-Hydroxy Midostaurin (CGP 52421), a metabolite of PKC412, effectively inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC₅₀s of approximately 132 nM and 9.8 μM in culture medium and plasma, respectively. 3-Hydroxy Midostaurin is less selective but more cytotoxic than PKC412 .

HY-W706452

Cabozantinib-d4 S-malate
Cabozantinib-d₄ (S-malate) (XL184-d₄ (S-malate); BMS-907351-d₄ (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-W751179

Midostaurin-13C6

Midostaurin- ¹³C₆ (PKC412- ¹³C₆) is the ¹³C-labeled Midostaurin (HY-10230). Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: